<bill session="116" type="h" number="1362" updated="2022-11-01T16:32:51Z">
  <state datetime="2019-02-26">REFERRED</state>
  <status>
    <introduced datetime="2019-02-26"/>
  </status>
  <introduced datetime="2019-02-26"/>
  <titles>
    <title type="display">Medical Innovation Never Stops Act of 2019</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to allow, during a lapse in appropriations, acceptance of certain device submissions and registrations with the corresponding fees made available for obligation and expenditure for the process for the review of device applications, and for other purposes.</title>
    <title type="short" as="introduced">Medical Innovation Never Stops Act of 2019</title>
  </titles>
  <sponsor bioguide_id="E000294"/>
  <cosponsors/>
  <actions>
    <action datetime="2019-02-26">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-02-26" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2019-02-27">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Appropriations"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Executive agency funding and structure"/>
    <term name="Licensing and registrations"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-12T14:50:28Z" status="Introduced in House">Medical Innovation Never Stops Act of 2019 

This bill requires the Food and Drug Administration (FDA)to accept and review new medical device applications and associated user fees during a lapse in appropriations.Under current law, the FDA is prohibited from accepting new user fees and reviewing medical device submissions during an appropriations lapse.</summary>
</bill>
